Skip to main content
SpringerLink
Log in

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease

  • Original Articles
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background and aims: Epidemiological studies have examined the association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Alzheimer’s disease (AD). Recently, a variety of experimental studies indicates that a subset of NSAIDs, such as ibuprofen or flurbiprofen, also have Aβ-lowering properties in both AD transgenic mice and cell cultures of peripheral, glial and neuronal origin. In this trial, we evaluated whether the non-selective NSAID ibuprofen slows disease progression in patients with mild to moderate AD. Methods: This was a 12-month multicenter, randomized, double-blind, placebo-controlled, parallel group trial. Participants with mild-moderate AD (Mini-Mental State Examination score >15, <26; Clinical Dementia Rating= 0.5–1), 65 years or older, with reliable caregivers, were recruited between April 2003 and September 2004. Seven AD Outpatient Treatment Centers screened 530 patients, 132 of whom were enrolled. Interventionconsisted of 400 mg ibuprofen twice a day or placebo, together with 20 mg once a day of esomeprazol, or placebo. The primary measure was any one-year change in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score. Secondary measures included changes in MMSE, CDR, Basic and Instrumental Activities of Daily Living scales, and Neuropsychiatry Inventory (NPI). Results: Fifty-one patients (77%) in the ibuprofen vs 46 (70%) in the placebo group completed the protocol (p>0.20). In intention-to-treat analysis, ADAS-Cog score worsening was similar in the two groups (p=0.951, treatment difference= 0.1, CI-2.7; 2.9). No differences were found for any secondary outcomes. In a subsample of genotyped patients, ApoE ε4 carriers treated with ibuprofen (n=27) were the only group without significant cognitive decline. Conclusions: Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD. Our results suggest the need to examine whether differences in the response to NSAIDs exist, based on ApoE ε4 carrier status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Akiyama H, Barger S, Barnum S et al. Neuroinflammation Working Group. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21: 383–421.

    Article  CAS  Google Scholar 

  2. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001; 58: 1790–2.

    Article  PubMed  CAS  Google Scholar 

  3. Pratico D, Trojanowski JQ. Inflammatory hypotheses: novel mechanisms of Alzheimer’s neurodegeneration and new therapeutic targets? Neurobiol Aging 2000; 21: 441–5.

    Article  PubMed  CAS  Google Scholar 

  4. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer’s disease: a study of epidemiological aspects. Ann Neurol 1984; 15: 335–41.

    Article  PubMed  CAS  Google Scholar 

  5. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol 1985; 121: 414–21.

    PubMed  CAS  Google Scholar 

  6. Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer’s type. Br J Rheumatol 1989; 28: 86–8.

    Article  PubMed  CAS  Google Scholar 

  7. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990; 335: 1037.

    Article  PubMed  CAS  Google Scholar 

  8. Broe GA, Henderson AS, Creasey H at al. A case-control study of Alzheimer’s disease in Australia. Neurology 1990; 40: 1698–707.

    Article  PubMed  CAS  Google Scholar 

  9. Graves AB, White E, Koepsell TD at al. A case-control study of Alzheimer’s disease. Ann Neurol 1990; 28: 766–74.

    Article  PubMed  CAS  Google Scholar 

  10. Breteler MM, van Duijn CM, Chandra Vet al. Medical history and the risk of Alzheimer’s disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991; 20 (Suppl. 2): S36–42.

    Article  PubMed  Google Scholar 

  11. Beard CM, Kokman E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer’s disease. Lancet 1991; 337: 1426.

    Article  PubMed  CAS  Google Scholar 

  12. Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer’s disease in China. Neurology 1992; 42: 1481–8.

    Article  PubMed  CAS  Google Scholar 

  13. The Canadian Study of Health and Aging: risk factors for Alzheimer’s disease in Canada. Neurology 1994; 44: 2073–80.

    Article  Google Scholar 

  14. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer’s disease. Biol Psychiatry 1994; 36: 854–6.

    Article  PubMed  CAS  Google Scholar 

  15. Myllykangas-Luosujarvi R, Isomaki H. Alzheimer’s disease and rheumatoid arthritis. Br J Rheumatol 1994; 33: 501–2.

    Article  PubMed  CAS  Google Scholar 

  16. Breitner JC, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994; 44: 227–32.

    Article  PubMed  CAS  Google Scholar 

  17. Breitner JC, Welsh KA, Helms MJ et al. Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523–30.

    Article  PubMed  CAS  Google Scholar 

  18. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology 1995; 45: 1441–5.

    Article  PubMed  CAS  Google Scholar 

  19. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 1995; 45: 51–5.

    Article  PubMed  CAS  Google Scholar 

  20. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48: 626–32.

    Article  PubMed  CAS  Google Scholar 

  21. Anthony JC, Breitner JC, Zandi PP et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 2000; 54: 2066–71.

    Article  PubMed  CAS  Google Scholar 

  22. Broe GA, Grayson DA, Creasey HM et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000; 57: 1586–91.

    Article  PubMed  CAS  Google Scholar 

  23. in t’Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001; 345: 1515–21.

    Article  Google Scholar 

  24. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC; Cache County Study Investigators. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002; 59: 880–6.

    Article  PubMed  CAS  Google Scholar 

  25. Henderson AS, Jorm AF, Christensen H, Jacomb PA, Korten AE. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 1997; 12: 926–30.

    Article  PubMed  CAS  Google Scholar 

  26. Fourrier A, Letenneur L, Begaud B, Dartigues JF. Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 1996; 49: 1201.

    Article  PubMed  CAS  Google Scholar 

  27. Beard CM, Waring SC, O’Brien PC, Kurland LT, Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998; 73: 951–5.

    Article  PubMed  CAS  Google Scholar 

  28. in t’Veld BA, Launer LJ, Hoes AW et al. NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging 1998; 19: 607–11.

    Article  Google Scholar 

  29. Aisen PS, Davis KL, Berg JD et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 2000; 54: 588–93.

    CAS  Google Scholar 

  30. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358: 455–60.

    Article  PubMed  Google Scholar 

  31. Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 2000; 20: 5709–14.

    PubMed  CAS  Google Scholar 

  32. Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212–6.

    Article  PubMed  CAS  Google Scholar 

  33. Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440–9.

    PubMed  CAS  Google Scholar 

  34. Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–11.

    Article  PubMed  CAS  Google Scholar 

  35. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999; 53: 197–201.

    Article  PubMed  CAS  Google Scholar 

  36. Aisen PS, Schafer KA, Grundman M et al; Alzheimer’s Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819–26.

    Article  PubMed  CAS  Google Scholar 

  37. Reines SA, Block GA, Morris JC et al; Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blind, controlled study. Neurology 2004; 62: 6–71.

    Article  Google Scholar 

  38. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 23: 8–21.

    Article  PubMed  CAS  Google Scholar 

  39. Topol EJ. Arthritis medicines and cardiovascular events—“house of coxibs”. JAMA 2005; 293: 366–8.

    Article  PubMed  CAS  Google Scholar 

  40. Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006; 1: e33.

  41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44.

    Article  PubMed  CAS  Google Scholar 

  42. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.

    CAS  Google Scholar 

  43. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412–4.

    Article  PubMed  CAS  Google Scholar 

  44. Hixson JE, Vernier DT. Restriction isotyping of human APOE by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545–8.

    PubMed  CAS  Google Scholar 

  45. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64.

    PubMed  CAS  Google Scholar 

  46. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37–49.

    Article  PubMed  Google Scholar 

  47. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist 1970; 10: 20–30.

    Article  PubMed  CAS  Google Scholar 

  48. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–86.

    Article  PubMed  CAS  Google Scholar 

  49. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14.

    Article  PubMed  CAS  Google Scholar 

  50. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–72.

    Article  PubMed  CAS  Google Scholar 

  51. Knopman DS, Knapp MJ, Gracon SI, Davis CS The Clinician Interview-Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology 1994; 44: 2315–21.

    Article  PubMed  CAS  Google Scholar 

  52. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto 1983.

    Google Scholar 

  53. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71.

    Article  PubMed  CAS  Google Scholar 

  54. Novak M, Guest C. Application of a multidimensional caregiver burden inventory. Gerontologist 1989; 29: 798–803.

    Article  PubMed  CAS  Google Scholar 

  55. Zandi PP, Breitner JC. Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001; 22: 811–7.

    Article  PubMed  CAS  Google Scholar 

  56. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci USA 2006; 11; 103: 5644–51.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Statistics & Information Technology, Fatebenefratelli Association for Research, Isola Tiberina, Rome, Italy

    Patrizio Pasqualetti & Luca Paulon

  2. Casa di Cura San Raffaele Cassino e IRCCS San Raffaele Pisana, Rome, Italy

    Patrizio Pasqualetti

  3. Alzheimer Unit, Memory Clinic, IRCCS Centro S. Giovanni di Dio — FBF, Via Pilastroni 4, 25125, Brescia, Italy

    Cristina Bonomini, Orazio Zanetti MD & Paolo Maria Rossini

  4. Department of Neurology, Medical College of Wisconsin, Milwaukee, USA

    Gloria Dal Forno

  5. Alzheimer Unit, Fondazione Istituto Neurologico C. Mondino, Pavia, Italy

    Elena Sinforiani

  6. Neuropsychological Unit, Department of Neuroscience, Catholic University, Rome, Italy

    Camillo Marra

  7. Department of Neurology, University Campus Bio-Medico, Rome, Italy

    Paolo Maria Rossini

Authors
  1. Patrizio Pasqualetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Bonomini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gloria Dal Forno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luca Paulon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Sinforiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Camillo Marra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Orazio Zanetti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paolo Maria Rossini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Orazio Zanetti MD.

Additional information

The preliminary results of this study were presented at: 10th International Conference of Alzheimer Disease and Related Disorders, July 17, 2006 (Poster Section); and 52nd Congress of the Italian Society of Geriatrics and Gerontology, December 1, 2007 (Oral Communication).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pasqualetti, P., Bonomini, C., Dal Forno, G. et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res 21, 102–110 (2009). https://doi.org/10.1007/BF03325217

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03325217

Keywords

Search

Navigation